Drug firm Lupin on Monday said its South African arm Pharma Dynamics has signed a commercial agreement with Creso Pharma for hemp oil-based cannaQIX products.
As per the agreement, Creso has given Pharma Dynamics sole distribution rights of its products across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda, Lupin said in a statement.
Pharma Dynamics CEO Erik Roos said, “We hope that this agreement will form the foundation of a longstanding relationship as we grow our footprint from nutraceuticals into the scheduled market as well.”
Creso Pharma is globally recognised as a leader in the production of cannabis products with distribution agreements already in place in various countries in Europe and Asia-Pacific, he added.
“We are encouraged to see a wide range of opportunities opening up to bring premium hemp oil nutraceutical products to customers in South Africa,” Creso Pharma CEO and co-founder Miri Halperin Wernli said.
The cannaQIX range of products are cannabidiol hemp oil-based nutraceuticals that are used for reducing stress and to support mental and nervous functions.
Shares of Lupin Ltd closed at ₹747.30 per scrip on the BSE, up 1.21 per cent from its previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.